MedPath

Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis

Phase 3
Completed
Conditions
Cirrhosis
Interventions
Device: BreathID (Methacetin breath test)
Registration Number
NCT01157845
Lead Sponsor
Virginia Commonwealth University
Brief Summary

The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
165
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Laboratory assayBreathID (Methacetin breath test)-
Primary Outcome Measures
NameTimeMethod
Mortality From Liver Failure1 year

Patient dies of liver-related causes within 1 year of study entry

Secondary Outcome Measures
NameTimeMethod
Liver Transplantation1 year

Patient experiences complications of liver failure within 1 year of study entry and undergoes liver transplantation

Trial Locations

Locations (4)

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Hadassah Medical Center

🇮🇱

Jerusalem, Israel

Virginia Commonwealth University Medical Center

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath